Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2025-10-03 Board/Management Inform…
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
Appointment of Marc Le Bozec as Interim CEO
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new interim CEO and the termination of the previous CEO at OSE Immunotherapeutics. This falls directly under the category of board and management changes, which is classified as 'MANG'.
2025-10-03 English
Nomination de Marc Le Bozec comme Directeur Général par interim
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new interim CEO (Marc Le Bozec) and the departure of the previous CEO (Nicolas Poirier) at OSE Immunotherapeutics. This falls directly under the category of management changes, which is defined as 'Announcement of changes in the company's board of directors or senior management'.
2025-10-03 French
Franchissements de seuils
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding 'Déclarations de franchissements de seuils' (Threshold crossing declarations). It details changes in share ownership and voting rights for OSE IMMUNOTHERAPEUTICS, specifically identifying a concert of shareholders and individual director holdings. This falls under the category of Major Shareholding Notifications (MRQ), which covers notifications of changes in significant share ownership levels.
2025-10-02 French
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
AGM Information Classification · 100% confidence The document is a press release announcing the results of an Annual General Meeting (AGM), specifically focusing on the election of a new Board of Directors and the appointment of a new Chairman. While it mentions the AGM, it is not the full presentation materials (AGM-R) nor a formal declaration of voting results (DVA), but rather a corporate announcement summarizing these events. Given the primary focus on the change in board leadership, 'MANG' (Board/Management Information) is the most accurate classification.
2025-09-30 English
Renouvellement complet du Conseil d'administration Élection du Dr Markus Cappel en tant que Président du Conseil d'administration
AGM Information Classification · 100% confidence The document is a press release announcing the results of an Annual General Meeting (AGM), specifically focusing on the election of a new Board of Directors and the appointment of a new Chairman. While it mentions voting participation percentages, it is primarily a corporate announcement regarding management changes and board composition following an AGM, rather than a formal, standalone voting results filing or a full AGM presentation deck. Given the focus on the board renewal and management appointment, it fits best under Board/Management Information.
2025-09-30 French
OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic partnership between OSE Immunotherapeutics, Inserm Transfert, and Nantes Université to accelerate innovation in immunotherapy. It details the nature of the collaboration, provides quotes from leadership, and includes standard corporate boilerplate information. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing for a specific corporate action like a dividend or share issue. Therefore, it falls under the general regulatory announcement category (RNS).
2025-09-26 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.